# Pathologist Analysis Report

## Analysis Output

# 病理学与影像学分析报告

## 1. 病理诊断概述

*   **原发肿瘤**: 乙状结肠恶性肿瘤
*   **组织学类型**: 腺癌 (Adenocarcinoma)
*   **分化程度**: 中分化 (Moderately differentiated)
*   **TNM 分期**: ypT4aN2aM1 (IV 期)
    *   *注*: "yp" 前缀表示新辅助治疗后的病理分期，提示原发灶穿透浆膜 (T4a) 且有 4-6 枚区域淋巴结转移 (N2a，病历显示 5/19 阳性)。
*   **转移部位**:
    *   既往: 肝脏 (已行根治性切除)
    *   当前: 双肺多发转移 (最大 2.1×1.5cm)
*   **治疗反应评估**: TRG 2 级 (Tumor Regression Grade)
    *   *解读*: 提示新辅助治疗后有部分肿瘤消退，但仍有显著残留病灶。

## 2. 免疫组化 (IHC) 与分子病理分析

### 2.1 关键生物标记物解读

| 标记物 | 结果 | 临床意义解读 |
| :--- | :--- | :--- |
| **MMR 蛋白** | MLH1(+), PMS2(+), MSH2(+), MSH6(+) | **pMMR (错配修复完整)**: 提示微卫星稳定 (MSS) 表型。通常对单药免疫治疗不敏感，需联合治疗。 |
| **KRAS** | **G12C 突变** (丰度 11.5%) | **负向预后因子 & 治疗靶点**: 导致抗 EGFR 单抗 (如西妥昔单抗) 单药耐药，但对 G12C 抑制剂敏感。 |
| **TMB** | **79 muts/MB** (高) | **异常发现**: MSS 肠癌通常 TMB 低 (<10)。79 属于超高突变，可能暗示 POLE/POLD1 突变，提示对免疫治疗潜在敏感性。 |
| **ATM** | **胚系突变** | **DNA 损伤修复缺陷**: 可能增加对铂类化疗 (奥沙利铂) 的敏感性，亦可能增加肿瘤免疫原性。 |
| **EGFR** | 2+ (过表达) | 虽有表达，但因下游 KRAS 突变，阻断 EGFR 需联合 KRAS 抑制剂才能生效 (阻断反馈回路)。 |
| **Ki-67** | +5% | **数值偏低**: 来源于术后标本，反映新辅助化疗后的细胞增殖抑制状态，**不代表**当前转移灶的活跃程度。 |
| **PD-L1** | CPS=3 | 低表达，但在结直肠癌中 PD-L1 预测价值有限，主要依赖 MSI/TMB 状态。 |

### 2.2 深度分析：矛盾的 TMB 与 MSS

*   **发现**: 患者为 MSS (微卫星稳定)，但 TMB 高达 79 muts/MB。
*   **病理学解释**: 绝大多数 MSS 结直肠癌 TMB 很低。此处的 "超高 TMB + MSS" 表型强烈提示存在 **POLE 或 POLD1 基因校对结构域突变**。
*   **临床相关性**: POLE 突变的结直肠癌虽然是 MSS，但因产生大量新抗原，通常对免疫检查点抑制剂 (ICI) 反应极佳。这解释了为何患者在三线治疗中使用信迪利单抗 (PD-1) 联合方案时曾观察到 "SD (缩小)" 和病情控制，尽管其为 MSS 表型。

## 3. 影像学分析

### 3.1 转移模式
*   **双肺多发转移**: 当前主要矛盾。最大病灶 2.1×1.5cm，属于可测量病灶 (RECIST 标准)。
*   **肝脏状态**: 既往有肝转移并切除，目前未提及复发，提示肝脏局部控制尚可，疾病呈 "寡转移" 向 "全身播散" 发展的趋势。

### 3.2 治疗反应与影像相关性
*   **一线 (奥沙利铂+贝伐)**: PR (部分缓解)。
    *   *机制推测*: ATM 胚系突变导致的同源重组修复缺陷 (HRD) 可能增强了肿瘤对铂类药物 (DNA 损伤剂) 的敏感性。
*   **近期 (疫苗+免疫)**: PD (进展)，肺部病灶增大。
    *   *解读*: 尽管 TMB 高，但多线治疗后肿瘤可能通过抗原丢失或免疫逃逸机制产生耐药。

## 4. 基于 cBioPortal 与文献的证据分析

### 4.1 KRAS G12C 在结直肠癌中的特征
*   **频率**: 根据 cBioPortal 及文献，KRAS G12C 在结直肠癌中发生率约为 **3-4%** (较非小细胞肺癌低)。
*   **预后**: 相比其他 KRAS 突变，G12C 携带者预后较差，且更容易出现肺转移 (符合该患者表现)。
*   **治疗逻辑**:
    *   *单药局限*: KRAS G12C 抑制剂单药治疗结直肠癌的有效率 (ORR) 仅约 10-20%，因为阻断 KRAS 会反馈性激活上游 EGFR 信号。
    *   *联合策略*: **KRAS G12C 抑制剂 + 抗 EGFR 单抗** (如氟泽雷赛 + 西妥昔单抗) 是标准策略。CodeBreaK 300 研究显示 Sotorasib + Panitumumab 显著延长 PFS [PMID: 40215429]。

### 4.2 ATM 胚系突变的意义
*   **文献支持**: ATM 突变涉及 DNA 双链断裂修复。在结直肠癌中，ATM 突变与较高的肿瘤突变负荷 (TMB) 相关，且可能预测对免疫治疗的获益 [PMID: 37232365]。
*   **临床吻合**: 患者的高 TMB 和对含铂化疗的初始敏感性与 ATM 功能缺失表型一致。

## 5. 病理学关键结论与提示

1.  **分子分型**: **KRAS G12C 突变型、MSS、TMB-High (POLE 样表型)、ATM 胚系突变型** 结直肠腺癌。
2.  **当前治疗病理依据**:
    *   **氟泽雷赛 (KRASi) + 西妥昔单抗 (EGFRi)**: 具有极强的病理学依据。KRAS G12C 是驱动基因，联合西妥昔单抗是为了克服单药治疗导致的 EGFR 反馈性激活耐药。这是目前针对该分子亚型的最佳循证治疗。
3.  **预后因素**:
    *   *不利*: KRAS G12C 突变、IV 期、多线治疗失败。
    *   *有利*: 高 TMB 可能保留对免疫治疗的一定敏感性 (若能克服微环境抑制)；ATM 突变提示对 DNA 损伤药物敏感。
4.  **监测建议**:
    *   由于 TMB 极高，肿瘤异质性大，建议密切监测 **ctDNA (液体活检)** 以评估 KRAS G12C 克隆的清除情况及获得性耐药突变 (如 MET 扩增、其他 RAS 突变) 的出现。

## 6. 参考文献

*   **[PMID: 34742312]** Zhu G, et al. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. *Mol Cancer*. 2021. (KRAS 预后与生物学功能)
*   **[PMID: 40215429]** Pietrantonio F, et al. Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab. *JCO*. 2025. (KRAS G12C 联合 EGFR 抑制剂的高级别证据)
*   **[PMID: 37232365]** Lin Y, et al. Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors. *Mol Carcinog*. 2023. (ATM 突变与免疫治疗敏感性)
*   **cBioPortal**: Colorectal Adenocarcinoma (MSK/TCGA datasets).

---

## Tool Call Details

### Tool Call 1: `search_cbioportal`
**Timestamp:** 2026-01-20 15:12:08

**Parameters:**
```json
{
  "variant": "G12C",
  "gene": "KRAS",
  "cancer_type": "Colorectal Adenocarcinoma"
}
```

**Result:**
```
**cBioPortal 查询结果**

**基因**: KRAS
**变异**: G12C
**变异计数**: 370
**总突变数**: 3452
**频率**: 10.72%
**肿瘤类型**: Colorectal Adenocarcinoma

**按癌症类型分布**:
- msk: 1670 mutations
- pancan: 1630 mutations
- brca: 14 mutations
- mds: 138 mutations

**常见突变 (Top 10)**:
- G12D: 944
- G12V: 713
- G13D: 391
- G12C: 370
- G12A: 185
- G12S: 123
- A146T: 121
- G12R: 111
- Q61H: 99
- G13C: 43

**参考**: https://www.cbioportal.org/results?cancer_study_list=msk_impact_2017&gene_list=KRAS&tab=summary
```

### Tool Call 2: `search_cbioportal`
**Timestamp:** 2026-01-20 15:12:09

**Parameters:**
```json
{
  "cancer_type": "Colorectal Adenocarcinoma",
  "gene": "ATM"
}
```

**Result:**
```
**cBioPortal 查询结果**

**基因**: ATM
**分析研究数**: 2
**肿瘤类型**: Colorectal Adenocarcinoma

**按癌症类型分布**:
- msk: 646 mutations
- pancan: 720 mutations

**常见突变 (Top 10)**:
- R337C: 35
- R250*: 23
- K2811Sfs*46: 17
- R3008H: 13
- S214Pfs*16: 11
- R3008C: 11
- R1730*: 10
- R35*: 8
- R2691C: 8
- E2304Gfs*69: 8

**参考**: https://www.cbioportal.org
```

### Tool Call 3: `search_pubmed`
**Timestamp:** 2026-01-20 15:12:12

**Parameters:**
```json
{
  "query": "KRAS G12C colorectal cancer prognosis treatment"
}
```

**Result:**
```
**PubMed 搜索结果**

**搜索关键词**: KRAS G12C colorectal cancer prognosis treatment
**找到文献**: 5 篇

---

### 1. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.

- **PMID**: 34742312
- **作者**: Zhu G, Pei L, Xia H
- **期刊**: Molecular cancer (2021)
- **摘要**: Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive activation of the KRAS protein, which acts as a molecular switch to persistently stimulate downstream signaling pathways, including cell proliferation and survival, thereby leading to tumorigenesis. Patients whose CRC harbors KRAS mutations have a dismal
- **链接**: https://pubmed.ncbi.nlm.nih.gov/34742312/

---

### 2. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.

- **PMID**: 38052910
- **作者**: Desai J, Alonso G, Kim SH
- **期刊**: Nature medicine (2024)
- **摘要**: KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C-positive CRC at 400 mg. Epidermal growth factor receptor has been recognized as a major upstream activator of RAS-MAPK signaling, a proposed key mechanism of resistance to KRAS G12C inhibition in CRC. Here, we report on divarasib plus cetuximab (epidermal growth factor receptor inhibitor) in patients wi
- **链接**: https://pubmed.ncbi.nlm.nih.gov/38052910/

---

### 3. Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory 

- **PMID**: 40215429
- **作者**: Pietrantonio F, Salvatore L, Esaki T
- **期刊**: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025)
- **摘要**: In the phase III CodeBreaK 300 study, sotorasib 960 mg-panitumumab significantly prolonged progression-free survival (PFS) versus investigator's choice (trifluridine/tipiracil or regorafenib) in patients with 
- **链接**: https://pubmed.ncbi.nlm.nih.gov/40215429/

---

### 4. Health-related quality of life in patients with KRAS

- **PMID**: 40812325
- **作者**: Modest DP, Fakih M, Salvatore L
- **期刊**: The Lancet. Oncology (2025)
- **摘要**: In the phase 3 CodeBreaK 300 study, sotorasib (KRAS
- **链接**: https://pubmed.ncbi.nlm.nih.gov/40812325/

---

### 5. KRAS inhibition in metastatic colorectal cancer: An update.

- **PMID**: 36638742
- **作者**: Nusrat M, Yaeger R
- **期刊**: Current opinion in pharmacology (2023)
- **摘要**: About half of colorectal cancers harbor mutations in the KRAS gene. The presence of these mutations is associated with worse prognosis and, until now, the absence of matched targeted therapy options. In this review, we discuss clinical efforts to target KRAS in colorectal cancer from studies of downstream inhibitors to recent direct inhibitors of KRAS
- **链接**: https://pubmed.ncbi.nlm.nih.gov/36638742/

---

```

### Tool Call 4: `search_pubmed`
**Timestamp:** 2026-01-20 15:12:13

**Parameters:**
```json
{
  "query": "ATM germline mutation colorectal cancer prognosis"
}
```

**Result:**
```
**PubMed 搜索结果**

**搜索关键词**: ATM germline mutation colorectal cancer prognosis
**找到文献**: 5 篇

---

### 1. Germline susceptibility variants impact clinical outcome and therapeutic strategies for stage III colorectal cancer.

- **PMID**: 30850667
- **作者**: Lin PC, Yeh YM, Wu PY
- **期刊**: Scientific reports (2019)
- **摘要**: Although somatic mutations are the main cause of cancer, underlying germline alterations may affect cancer outcome. There is little information on comprehensive analysis of germline genome sequencing for cancer healthcare strategy. Here we studied the implication of germline cancer-associated variants on cancer counselling and therapeutic strategies by germline whole genome and tumor targeted sequencing. Fifty-five gynecological and 104 colorectal cancer (CRC) patients were enrolled. We identifi
- **链接**: https://pubmed.ncbi.nlm.nih.gov/30850667/

---

### 2. Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine.

- **PMID**: 30730459
- **作者**: You YN, Borras E, Chang K
- **期刊**: Diseases of the colon and rectum (2019)
- **摘要**: Genomic profiling of colorectal cancer aims to identify actionable somatic mutations but can also discover incidental germline findings.
- **链接**: https://pubmed.ncbi.nlm.nih.gov/30730459/

---

### 3. Familial pancreatic cancer: genetic advances.

- **PMID**: 24395243
- **作者**: Rustgi AK
- **期刊**: Genes & development (2014)
- **摘要**: Beset by poor prognosis, pancreatic ductal adenocarcinoma is classified as familial or sporadic. This review elaborates on the known genetic syndromes that underlie familial pancreatic cancer, where there are opportunities for genetic counseling and testing as well as clinical monitoring of at-risk patients. Such subsets of familial pancreatic cancer involve germline cationic trypsinogen or PRSS1 mutations (hereditary pancreatitis), BRCA2 mutations (usually in association with hereditary breast-
- **链接**: https://pubmed.ncbi.nlm.nih.gov/24395243/

---

### 4. The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancer.

- **PMID**: 40515474
- **作者**: Jiang B, Shang Y, Zhang X
- **期刊**: The oncologist (2025)
- **摘要**: The homologous recombination (HR) system repairs DNA double-strand breaks produced by the DNA damage response, which is a complex signaling pathway consisting of the key proteins BRCA1/2 and other DNA repair proteins, such as the ATM, PALB2, BARD1, RAD51, and Fanconi anemia proteins. Mutations and epigenetic alterations in HR-related genes may lead to homologous recombination deficiency (HRD), resulting in genomic instability and contributing to the development of certain solid tumors. The biolo
- **链接**: https://pubmed.ncbi.nlm.nih.gov/40515474/

---

### 5. Expanding the spectrum of germline variants in cancer.

- **PMID**: 28975465
- **作者**: Siraj AK, Masoodi T, Bu R
- **期刊**: Human genetics (2017)
- **摘要**: Our ability to identify germline variants in hereditary cancer cases remains challenged by the incomplete cataloging of relevant genes and lack of consensus on who should be tested. We designed a panel [hereditary oncogenesis predisposition evaluation (HOPE)] that encompasses most of the genes known to be associated with cancer development and tested its yield on more than 1300 samples of cancer patients. Pathogenic or likely pathogenic variants in high and intermediate risk genes were identifie
- **链接**: https://pubmed.ncbi.nlm.nih.gov/28975465/

---

```

### Tool Call 5: `search_pubmed`
**Timestamp:** 2026-01-20 15:12:14

**Parameters:**
```json
{
  "query": "high TMB MSS colorectal cancer prognosis immunotherapy"
}
```

**Result:**
```
**PubMed 搜索结果**

**搜索关键词**: high TMB MSS colorectal cancer prognosis immunotherapy
**找到文献**: 5 篇

---

### 1. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.

- **PMID**: 32379280
- **作者**: Chen EX, Jonker DJ, Loree JM
- **期刊**: JAMA oncology (2020)
- **摘要**: Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H).
- **链接**: https://pubmed.ncbi.nlm.nih.gov/32379280/

---

### 2. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.

- **PMID**: 33035640
- **作者**: Lizardo DY, Kuang C, Hao S
- **期刊**: Biochimica et biophysica acta. Reviews on cancer (2020)
- **摘要**: Colorectal cancers (CRCs) with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) often have sustained responses to immune checkpoint inhibitors (ICIs) including selective monoclonal antibodies against Program Death 1 (PD-1), Programmed Death Ligand 1(PD-L1), and cytotoxic T lymphocyte associated antigen 4 (CTLA-4). However, a substantial fraction of dMMR CRCs do not respond or ultimately develop resistance to immunotherapy. The majority (~85%) of CRCs are MMR proficient
- **链接**: https://pubmed.ncbi.nlm.nih.gov/33035640/

---

### 3. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.

- **PMID**: 32210966
- **作者**: Picard E, Verschoor CP, Ma GW
- **期刊**: Frontiers in immunology (2020)
- **摘要**: Colorectal cancer (CRC) is highly heterogeneous at the genetic and molecular level, which has major repercussions on the efficacy of immunotherapy. A small subset of CRCs exhibit microsatellite instability (MSI), a molecular indicator of defective DNA mismatch repair (MMR), but the majority are microsatellite-stable (MSS). The high tumor mutational burden (TMB) and neoantigen load in MSI tumors favors the infiltration of immune effector cells, and antitumor immune responses within these tumors a
- **链接**: https://pubmed.ncbi.nlm.nih.gov/32210966/

---

### 4. Patient-derived colorectal microtumors predict response to anti-PD-1 therapy.

- **PMID**: 40873566
- **作者**: Nguyen DT, Schaller MA, Terracina KP
- **期刊**: Frontiers in immunology (2025)
- **摘要**: Immune checkpoint inhibitors have made remarkable impacts in treating various cancers, including colorectal cancer (CRC). However, CRC still remains a leading cause of cancer-related deaths. While microsatellite instability (MSI) CRC has shown positive responses to anti-PD-1 therapy, this subgroup represents a minority of all CRC patients. Extensive research has focused on identifying predictive biomarkers to understand treatment response in CRC. Interestingly, a growing number of clinical cases
- **链接**: https://pubmed.ncbi.nlm.nih.gov/40873566/

---

### 5. Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors.

- **PMID**: 37232365
- **作者**: Lin Y, Luo S, Luo M
- **期刊**: Molecular carcinogenesis (2023)
- **摘要**: Immune checkpoint inhibitor (ICI) therapy is insensitive for Colorectal cancer (CRC) patients with microsatellite stable (MSS). Genomic data of three CRC cohort, n = 35), and the Cancer Genome Atlas (TCGA CRC cohort, n = 377), were analyzed. A cohort treated with ICIs from Memorial Sloan Kettering Cancer Center (MSKCC CRC cohort, n = 110) and two cases from the local hospital were characterized the impact of the HRR mutation on prognosis of CRC. Homologous recombination repair (HRR) gene mutatio
- **链接**: https://pubmed.ncbi.nlm.nih.gov/37232365/

---

```
